Thus, definitive answers concerning efficacy must be obtained through this 
clinical trial. 
I Time (days) 
I 
I 
I 
Figure 3: Growth curves are shown for 10* cells/well seeded in 12 well plates. H322a cells were infected by 
incubation 0.5 ml of viral supernate stock from either LNSX or LNSX-p53 (10* CFU/ml ) on 2 
consecutive days (beginning at day -2) in the presence of ^/ml of polybrene. Cells were not 
selected with 6418. Cells were counted daily. The mean ± SE is shown for three replicates. 
Time (days) 
Figure 4 : Growth curves are shown for 10* cells/well seeded in 12 well plates. H358a cells were infected by 
incubation 0.5 m of viral supernate stock from either LNSX or LNSX- p53 (10* CFU/ml) in the 
presence of £|^/ml of polybrene. The parental H358a cells served as a control. Cells were not 
selected with 6418. Cells were counted daily. The mean ± SE is shown for three replicates. 
i 
i 
I 
1 
I 
I 
Recombinant DNA Research, Volume 19 
[285] 
